• Explore /
  • Poster
  • / Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.

Abstract Poster

Authors

Yoon-Koo Kang

Yoon-Koo Kang

Departments of Oncology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea

Yoon-Koo Kang , Taroh Satoh , Min-Hee Ryu , Yee Chao , Ken Kato , Hyun Cheol Chung , Jen-Shi Chen , Kei Muro , Won Ki Kang , Takaki Yoshikawa , Sang Cheul Oh , Takao Tamura , Keun-Wook Lee , Narikazu Boku , Li-Tzong Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02267343

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 2)

DOI

10.1200/JCO.2017.35.4_suppl.2

Abstract #

2

Poster Bd #

D2

Abstract Disclosures

Similar Posters

First Author: Ronan Joseph Kelly

First Author: Nick Pavlakis

First Author: Markus H. Moehler

First Author: Markus H. Moehler